Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Selective degradation of splicing factor CAPERα by anticancer sulfonamides

(2017) Taisuke Uehara et al.   Nature Chemical Biology

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

(2017) Ting Han et al.   SCIENCE

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation

(2015) Emil Bulatov et al.   BIOCHEMICAL JOURNAL

Emerging therapeutic drugs for AML

(2015) E. M. Stein et al.   BLOOD

Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

(2014) Naveen Pemmaraju et al.   AMERICAN JOURNAL OF HEMATOLOGY

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

(2014) R B Walter et al.   LEUKEMIA

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

(2013) R. Luthra et al.   HAEMATOLOGICA

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment

(2012) Yoichi Ozawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis

(2010) Jacob M. Rowe et al.   CANCER

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

(2008) W S Siegel-Lakhai et al.   BRITISH JOURNAL OF CANCER